December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evaxion A/S - American Depositary Share (NQ:EVAX)

3.070 +0.030 (+0.99%)
Delayed Quote Updated: 9:40 AM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evaxion A/S - American Depositary Share

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 104.5% to $0.1916. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Are Evaxion Biotech Shares Trading Higher Today ↗
 
Via Benzinga
News headline image
Why Is Cancer Immunotherapy Focused Evaxion Biotech Stock Trading Higher Today? ↗
Evaxion Biotech A/S (NASDAQ: EVAX) collaborated with Afrigen Biologics to develop a prophylactic vaccine based on Evaxion's EDEN-discovered  
Via Benzinga
News headline image
Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea
From Evaxion Biotech
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
From Evaxion Biotech
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time to start the day off with a breakdown of the biggest pre-market stock movers worth watching on Tuesday morning! 
Via InvestorPlace
News headline image
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development
From Evaxion Biotech
Via GlobeNewswire
News headline image
Evaxion announces Executive Management Changes to strengthen the AI-strategy
From Evaxion Biotech
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Evaxion Announces Business Update and Second Quarter 2023 Financial Results
From Evaxion Biotech
Via GlobeNewswire
News headline image
Evaxion announces financing commitments totaling up to USD 20 million with Negma Group
From Evaxion Biotech
Via GlobeNewswire
News headline image
Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus
From Evaxion Biotech
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Mallinckrodt Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket ↗
Gainers Forza X1, Inc. (NASDAQ: FRZA) shares rose 85.6% to $2.32 in pre-market trading after the company tweeted Friday 'Get ready for something extraordinary! Stay tuned!' 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
It's time to start the week off right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
News headline image
Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial
From Evaxion Biotech
Via GlobeNewswire
News headline image
Evaxion Announces Business Update and First Quarter 2023 Financial Results
From Evaxion Biotech
Via GlobeNewswire
News headline image
Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines
From Evaxion Biotech
Via GlobeNewswire
News headline image
Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01
From Evaxion Biotech
Via GlobeNewswire
News headline image
Evaxion to host R&D Day on May 25, 2023
From Evaxion Biotech
Via GlobeNewswire
News headline image
Fourth quarter and full year 2022 financial results and business update
From Evaxion Biotech
Via GlobeNewswire
News headline image
Evaxion Biotech Says Personalized Cancer Immunotherapy Meets Primary Endpoint In Melanoma Patients ↗
 
Via Benzinga
News headline image
Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional... 
Via Benzinga
News headline image
Evaxion announces promising clinical data for DNA-based personalized cancer immunotherapy EVX-02: Phase 1/2a trial met both primary and secondary endpoints
From Evaxion Biotech
Via GlobeNewswire
News headline image
Evaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platform
From Evaxion Biotech
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.